Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    An open label, multicenter pasireotide roll over protocol for patients who have completed a previous Novartis sponsored pasireotide study and are judged by the investigator to benefit from continued pasireotide treatment

    Summary
    EudraCT number
    2013-000267-84
    Trial protocol
    IT   BE   ES   GR   FR   PL   PT   BG  
    Global end of trial date
    25 Jul 2023

    Results information
    Results version number
    v1(current)
    This version publication date
    20 Feb 2025
    First version publication date
    20 Feb 2025
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    CSOM230B2412
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT01794793
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Recordati AG
    Sponsor organisation address
    Uferstrasse 90, , Basel, Switzerland,
    Public contact
    Clinical Trial Information Desk, Recordati AG, clinicaltrials.endocrinology@recordati.com
    Scientific contact
    Clinical Trial Information Desk, Recordati AG, clinicaltrials.endocrinology@recordati.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    29 Sep 2023
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    25 Jul 2023
    Global end of trial reached?
    Yes
    Global end of trial date
    25 Jul 2023
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The purpose of this study is to evaluate long term safety data and allow continued use of pasireotide in patients who are on pasireotide treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator
    Protection of trial subjects
    Not applicable
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    25 May 2013
    Long term follow-up planned
    Yes
    Long term follow-up rationale
    Safety
    Long term follow-up duration
    3 Months
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Poland: 30
    Country: Number of subjects enrolled
    Netherlands: 2
    Country: Number of subjects enrolled
    Portugal: 3
    Country: Number of subjects enrolled
    Spain: 2
    Country: Number of subjects enrolled
    Belgium: 37
    Country: Number of subjects enrolled
    Bulgaria: 4
    Country: Number of subjects enrolled
    France: 14
    Country: Number of subjects enrolled
    Germany: 12
    Country: Number of subjects enrolled
    Greece: 2
    Country: Number of subjects enrolled
    Hungary: 3
    Country: Number of subjects enrolled
    Italy: 12
    Country: Number of subjects enrolled
    Argentina: 6
    Country: Number of subjects enrolled
    India: 20
    Country: Number of subjects enrolled
    Israel: 2
    Country: Number of subjects enrolled
    Japan: 6
    Country: Number of subjects enrolled
    Korea, Republic of: 3
    Country: Number of subjects enrolled
    Malaysia: 6
    Country: Number of subjects enrolled
    Mexico: 10
    Country: Number of subjects enrolled
    Peru: 16
    Country: Number of subjects enrolled
    Brazil: 65
    Country: Number of subjects enrolled
    Romania: 8
    Country: Number of subjects enrolled
    Russian Federation: 16
    Country: Number of subjects enrolled
    Switzerland: 2
    Country: Number of subjects enrolled
    Taiwan: 2
    Country: Number of subjects enrolled
    Türkiye: 16
    Country: Number of subjects enrolled
    United States: 16
    Country: Number of subjects enrolled
    Thailand: 15
    Country: Number of subjects enrolled
    Canada: 7
    Worldwide total number of subjects
    337
    EEA total number of subjects
    129
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    305
    From 65 to 84 years
    32
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    -

    Pre-assignment
    Screening details
    Eligible patients were consented and subsequently continued their treatment with pasireotide using the same formulation they were receiving in the parent study at roll-over.

    Period 1
    Period 1 title
    Treatment period
    Is this the baseline period?
    Yes
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Pasireotide subcutaneous
    Arm description
    0.3mg, 0.6mg and 0.9mg. Doses to be taken BID or TID, dependent on parent study guidelines. Cabergoline may be combined in this arm for Cushing's Disease and Acromegaly patients.
    Arm type
    Experimental

    Investigational medicinal product name
    Pasireotide
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Administered subcutaneously in strengths 0.3mg, 0.6mg and 0.9mg. Doses to be taken BID or TID, dependent on parent study guidelines.

    Arm title
    Pasireotide LAR
    Arm description
    10mg, 20mg, 40mg and 60mg. All doses to be taken q28days. Strength is dependent on parent study guidelines.
    Arm type
    Experimental

    Investigational medicinal product name
    Pasireotide
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Powder and solvent for prolonged-release suspension for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Long Acting Release is administered by a single intramuscular (i.m.) monthly injection. The strengths are 10mg, 20mg, 40mg and 60mg. All doses to be taken q28days. Strength is dependent on parent study guidelines.

    Number of subjects in period 1
    Pasireotide subcutaneous Pasireotide LAR
    Started
    38
    299
    Completed
    22
    217
    Not completed
    16
    82
         Adverse event, serious fatal
    1
    5
         Consent withdrawn by subject
    6
    18
         not requiring treatment
    1
    -
         Adverse event, non-fatal
    3
    14
         Lost to follow-up
    -
    7
         patient not longer requiring treatment
    -
    13
         administrative problem
    1
    2
         Lack of efficacy
    4
    18
         Protocol deviation
    -
    5
    Period 2
    Period 2 title
    Post-treatment Follow-up
    Is this the baseline period?
    No
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Pasireotide subcutaneous
    Arm description
    0.3mg, 0.6mg and 0.9mg. Doses to be taken BID or TID, dependent on parent study guidelines. Cabergoline may be combined in this arm for Cushing's Disease and Acromegaly patients.
    Arm type
    Experimental

    Investigational medicinal product name
    Pasireotide
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Administered subcutaneously in strengths 0.3mg, 0.6mg and 0.9mg. Doses to be taken BID or TID, dependent on parent study guidelines.

    Arm title
    Pasireotide LAR
    Arm description
    Administered subcutaneously in strengths 0.3mg, 0.6mg and 0.9mg. Doses to be taken BID or TID, dependent on parent study guidelines.
    Arm type
    Experimental

    Investigational medicinal product name
    Pasireotide
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Powder and solvent for prolonged-release suspension for injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Long Acting Release is administered by a single intramuscular (i.m.) monthly injection. The strengths are 10mg, 20mg, 40mg and 60mg. All doses to be taken q28days. Strength is dependent on parent study guidelines.

    Number of subjects in period 2 [1]
    Pasireotide subcutaneous Pasireotide LAR
    Started
    19
    130
    Completed
    11
    99
    Not completed
    8
    31
         Consent withdrawn by subject
    2
    4
         Adverse event, non-fatal
    2
    6
         Lost to follow-up
    -
    3
         administrative problem
    2
    3
         Lack of efficacy
    2
    12
         Protocol deviation
    -
    3
    Notes
    [1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.
    Justification: Follow-up for safety evaluation 30 days following last dose of the s.c. formulation or 84 days following last dose of the LAR formulation (based on study completion CRF). In order to be consistent with previous reports, patients who completed study treatment were also included here. The number of participants to start the follow-up Period is not equal to the number who completed previous Period as they did not continued the study.

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Treatment period
    Reporting group description
    -

    Reporting group values
    Treatment period Total
    Number of subjects
    337 337
    Age categorical
    Units: Subjects
        In utero
    0 0
        Preterm newborn infants (gestational age < 37 wks)
    0 0
        Newborns (0-27 days)
    0 0
        Infants and toddlers (28 days-23 months)
    0 0
        Children (2-11 years)
    0 0
        Adolescents (12-17 years)
    0 0
        Adults (18-64 years)
    305 305
        From 65-84 years
    32 32
        85 years and over
    0 0
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    47.6 ( 12.43 ) -
    Gender categorical
    Units: Subjects
        Female
    190 190
        Male
    147 147

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Pasireotide subcutaneous
    Reporting group description
    0.3mg, 0.6mg and 0.9mg. Doses to be taken BID or TID, dependent on parent study guidelines. Cabergoline may be combined in this arm for Cushing's Disease and Acromegaly patients.

    Reporting group title
    Pasireotide LAR
    Reporting group description
    10mg, 20mg, 40mg and 60mg. All doses to be taken q28days. Strength is dependent on parent study guidelines.
    Reporting group title
    Pasireotide subcutaneous
    Reporting group description
    0.3mg, 0.6mg and 0.9mg. Doses to be taken BID or TID, dependent on parent study guidelines. Cabergoline may be combined in this arm for Cushing's Disease and Acromegaly patients.

    Reporting group title
    Pasireotide LAR
    Reporting group description
    Administered subcutaneously in strengths 0.3mg, 0.6mg and 0.9mg. Doses to be taken BID or TID, dependent on parent study guidelines.

    Primary: Incidence of adverse events to evaluate long term safety data

    Close Top of page
    End point title
    Incidence of adverse events to evaluate long term safety data [1]
    End point description
    The Safety Set included all patients who received at least one dose of study medication (pasireotide) after enrolling into the roll-over protocol
    End point type
    Primary
    End point timeframe
    Up to approximately 10 years
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The assessment of safety was based on the frequency and severity of AEs, adverse events of special interest (AESIs), and SAEs; summarised descriptively overall and by indication and formulation. No formal analyses were performed beyond descriptive statistics, and no hypotheses were tested.
    End point values
    Pasireotide subcutaneous Pasireotide LAR
    Number of subjects analysed
    38
    299
    Units: partecipants
    number (not applicable)
        AE: all grades
    26
    239
        AEs : Grades ≥3
    9
    93
        Treatment-related AEs : All grades
    13
    114
        Treatment-related AEs : Grades ≥3
    2
    27
        SAEs : All grades
    10
    81
        SAEs : Grades ≥3
    1
    66
        Fatal SAEs : All grades
    1
    7
        Treatment-related fatal SAEs : All grades
    0
    0
        Treatment-related fatal SAEs : Grades ≥3
    0
    0
        AEs leading to discontinuation : All grades
    3
    17
        AEs leading to discontinuation : Grades ≥3
    1
    10
        TAEs leading to discontinuation: all grades
    3
    13
        TAEs leading to discontinuation: Grades ≥3
    1
    6
        AEs leading to dose adjustment/interruption: All
    4
    35
        AEs leading to dose adjustment/interruption :G ≥3
    0
    13
        AEs requiring additional therapy : All
    17
    203
        AEs requiring additional therapy : Grades ≥3
    4
    58
    No statistical analyses for this end point

    Secondary: Percentage of patients with clinical benefit as assessed by the investigator

    Close Top of page
    End point title
    Percentage of patients with clinical benefit as assessed by the investigator
    End point description
    Efficacy was assessed by the investigator at each scheduled visit using a binary (yes/no) response confirming the investigator’s judgement of clinical benefit (via the question: “Does investigator confirm that the subject continues to have clinical benefit from the study treatment”). No other measures of efficacy were used in this study.
    End point type
    Secondary
    End point timeframe
    up to approximately 10 years
    End point values
    Pasireotide subcutaneous Pasireotide LAR
    Number of subjects analysed
    38
    299
    Units: partecipants
    number (not applicable)
        month 3
    29
    256
        month 6
    28
    250
        month 12
    21
    234
        month 18
    19
    216
        month 24
    17
    198
        month 36
    14
    177
        month 48
    15
    162
        month 60
    12
    140
        month 72
    12
    98
        month 84
    8
    21
        month 96
    5
    1
        month 108
    5
    1
        month 120
    0
    2
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Pasireotide s.c.: From start of study treatment up to 1 month after study treatment discontinuation (about 10 years) Pasireotide LAR: From start of study treatment up to 3 months after study treatment discontinuation (about 10 years)
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    23.0
    Reporting groups
    Reporting group title
    All partecipants
    Reporting group description
    -

    Serious adverse events
    All partecipants
    Total subjects affected by serious adverse events
         subjects affected / exposed
    91 / 337 (27.00%)
         number of deaths (all causes)
    8
         number of deaths resulting from adverse events
    8
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Adenocarcinoma of colon
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Colon cancer
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Leiomyoma
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Lung neoplasm
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Pituitary tumour recurrent
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Prostate cancer metastatic
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Thyroid cancer
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Vascular disorders
    Aortic aneurysm
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    deep vein thrombosis
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Distributive shock
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Hypertensive emergency
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Peripheral arterial occlusive disease
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Peripheral embolism
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    Thrombophlebitis
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    General disorders and administration site conditions
    Asthenia
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    General physical health deterioration
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Multiple organ dysfunction syndrome
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Non-cardiac chest pain
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Oedema peripheral
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Reproductive system and breast disorders
    Breast pain
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Menorrhagia
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Metrorrhagia
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Pulmonary embolism
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Acute respiratory failure
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Chronic obstructive pulmonary disease
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Respiratory failure
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Investigations
    Hepatic enzyme increased
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Weight decreased
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Injury, poisoning and procedural complications
    Femur fracture
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    joint injury
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Meniscus injury
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Poisoning
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Suture related complication
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Upper limb fracture
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Cardiac disorders
    Acute myocardial infarction
         subjects affected / exposed
    2 / 337 (0.59%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Cardiac failure
         subjects affected / exposed
    2 / 337 (0.59%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 2
    Coronary artery disease
         subjects affected / exposed
    2 / 337 (0.59%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Myocardial infarction
         subjects affected / exposed
    2 / 337 (0.59%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Angina pectoris
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Arrhythmia
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Cardiorespiratory arrest
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Myocardial Ischaemia
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Syringomyelia
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Nervous system disorders
    Epilepsy
         subjects affected / exposed
    2 / 337 (0.59%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Cerebrovascular accident
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Dementia
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Headache
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Hypoglycaemic coma
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Hypoglycaemic seizure
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Myasthenia gravis
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Transient Ischaemic attack
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Confusional state
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Depression
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Mental disorder
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Psychiatric decompensation
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Blood and lymphatic system disorders
    Febrile neutropenia
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Eye disorders
    Cataract
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Gastrointestinal disorders
    Abdominal adhesion
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Abdominal fat apron
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Anal fistula
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Enteritis
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Gastrointestinal haemorrhage
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Large Intestin Polyp
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Pancreatitis
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Pancreatitis acute
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Small intestinal obstruction
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Stasis Syndrome
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Umbelical hernia
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Hepatobiliary disorders
    Cholelithiasis
         subjects affected / exposed
    9 / 337 (2.67%)
         occurrences causally related to treatment / all
    8 / 9
         deaths causally related to treatment / all
    0 / 0
    Cholecystitis
         subjects affected / exposed
    5 / 337 (1.48%)
         occurrences causally related to treatment / all
    3 / 5
         deaths causally related to treatment / all
    0 / 0
    Cholangitis chronic
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Cholecystitis acute
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Cholecystitis chronic
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Hydrocholecystitis
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Hyperbilirubinaemia
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Renal and urinary disorders
    Nephrolithiasis
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 6
         deaths causally related to treatment / all
    0 / 0
    Acute kidney injury
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Renal failure
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Endocrine disorders
    Adrenal insufficiency
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Hyperadrenocorticism
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Musculoskeletal and connective tissue disorders
    back pain
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Foot deformity
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Muscular weakness
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Neck mass
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Tendon disorder
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Infections and infestations
    COVID-19
         subjects affected / exposed
    8 / 337 (2.37%)
         occurrences causally related to treatment / all
    0 / 8
         deaths causally related to treatment / all
    0 / 1
    Cellulitis
         subjects affected / exposed
    4 / 337 (1.19%)
         occurrences causally related to treatment / all
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    Appendicitis
         subjects affected / exposed
    3 / 337 (0.89%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    COVID-19 pneumonia
         subjects affected / exposed
    2 / 337 (0.59%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Septic shock
         subjects affected / exposed
    2 / 337 (0.59%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 1
    Abscess jaw
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Acute sinusitis
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Coronavirus infection
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Diarrhoea infectious
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Endocarditis
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Erysipelas
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Furuncle
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Gastroenteritis
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Infected dermal cyst
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Influenza
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Meningitis
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    peritonitis
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Pneunomia pseudomonal
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Pneumonia viral
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Post procedural infection
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Pyelonephritis acute
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Sepsis
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Sinusitis
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Suspected COVID-19
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Urinary tract infection
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Viral upper respiratory tract infection
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Metabolism and nutrition disorders
    Diabetic ketoacidosis
         subjects affected / exposed
    2 / 337 (0.59%)
         occurrences causally related to treatment / all
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    Hypoglycaemia
         subjects affected / exposed
    2 / 337 (0.59%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Diabetes mellitus
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Diabetic ketosis
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Diabetic metabolic decompesation
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Hyperglycaemia
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Hyponatraemia
         subjects affected / exposed
    1 / 337 (0.30%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    All partecipants
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    220 / 337 (65.28%)
    Vascular disorders
    Hypertension
         subjects affected / exposed
    25 / 337 (7.42%)
         occurrences all number
    25
    Nervous system disorders
    Headache
         subjects affected / exposed
    22 / 337 (6.53%)
         occurrences all number
    22
    Gastrointestinal disorders
    Diarrhoea
         subjects affected / exposed
    17 / 337 (5.04%)
         occurrences all number
    17
    Musculoskeletal and connective tissue disorders
    Back pain
         subjects affected / exposed
    30 / 337 (8.90%)
         occurrences all number
    30
    Infections and infestations
    Nasopharyngitis
         subjects affected / exposed
    32 / 337 (9.50%)
         occurrences all number
    32
    COVID-19
         subjects affected / exposed
    20 / 337 (5.93%)
         occurrences all number
    20
    Urinary tract infection
         subjects affected / exposed
    19 / 337 (5.64%)
         occurrences all number
    19
    Influenza
         subjects affected / exposed
    18 / 337 (5.34%)
         occurrences all number
    18
    Metabolism and nutrition disorders
    Hyperglycaemia
         subjects affected / exposed
    23 / 337 (6.82%)
         occurrences all number
    23
    Diabetes mellitus
         subjects affected / exposed
    18 / 337 (5.34%)
         occurrences all number
    18

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    11 Mar 2016
    Clarified the main objective of this study, the previous secondary objective “To collect long-term data on serious adverse events and adverse events of special interest” was elevated to primary objective. In addition, the protocol was amended to clarify the safety monitoring guidance and to include the collection of all AEs (including non-serious AEs) and an investigator attestation of continued clinical benefit.
    29 Sep 2017
     Included language on the trial end date to meet the regulatory guidelines of the Medicine and Health Research Authority, in the United Kingdom (UK).  Clarified that this trial was deemed to be a voluntary PASS by Novartis Regulatory Affairs in 2016. An interim analysis was to be performed in 2017, and every 2 years thereafter, until the final database lock.  Clarified the visit schedules for patients taking pasireotide s.c. and those taking pasireotide LAR, and further highlighted the required timelines for using highly effective methods of contraception after last dose of study medication
    08 Mar 2018
    The main purpose of this amendment is to: • Update the trial selection criteria to allow patients from Novartis-sponsored trials, being treated with pasireotide alone or in combination with another treatment for Cushing’s Disease and Acromegaly, to participate in this study. Several of the participating parent protocols permit for pasireotide to be administered in combination with another medical therapy. Revising the selection criteria would ensure those patients receiving clinical benefit would have continued access to the combination treatment. Combination treatment through this rollover would only be available for patients with Cushing’s Disease or Acromegaly.
    06 May 2020
    Since Novartis had signed an agreement to transfer the worldwide rights of Signifor® and Signifor® LAR to Recordati, all applicable sections of the protocol updated to substitute the name of the current sponsor Novartis with the name of the new sponsor Recordati or of IQVIA on behalf of Recordati, as applicable.
    02 Nov 2021
    It is anticipated that pasireotide will not be commercially available and reimbursed in all participating countries at study end. In order to ensure that patients deriving clinical benefit from pasireotide will continue receiving treatment with this drug outside the frame of the clinical trial, they will be allowed to obtain pasireotide through country-specific programmes as soon as they become available – even prior to the end of the study. This will ensure treatment continuity (applicable to Brazil, France, Germany, India, Italy, Malaysia, Mexico, Peru and Thailand)

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 23:47:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA